Franco Cecchi

Active 1989–2025

80
Papers
24,995
Citations
63
h-index
80
i10-index

Citations

Citations per year for Franco Cecchi1982: 6 citations1986: 2 citations1988: 1 citations1991: 5 citations1992: 1 citations1993: 2 citations1994: 3 citations1995: 2 citations1996: 1 citations1997: 10 citations1998: 10 citations1999: 12 citations2000: 14 citations2001: 16 citations2002: 25 citations2003: 51 citations2004: 46 citations2005: 54 citations2006: 42 citations2007: 69 citations2008: 66 citations2009: 108 citations2010: 149 citations2011: 209 citations2012: 145 citations2013: 152 citations2014: 214 citations2015: 185 citations2016: 203 citations2017: 204 citations2018: 212 citations2019: 667 citations2020: 838 citations2021: 807 citations2022: 557 citations2023: 500 citations2024: 751 citations2025: 302 citations2026: 7 citations1983–1985: no citations, so these years are not shown1987: no citations, so this year is not shown1989–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,475 citing papers, 19.6% of this breakdownItaly: 821 citing papers, 10.9% of this breakdownUnited Kingdom: 769 citing papers, 10.2% of this breakdownGermany: 425 citing papers, 5.6% of this breakdownNetherlands: 359 citing papers, 4.8% of this breakdownChina: 340 citing papers, 4.5% of this breakdownSpain: 271 citing papers, 3.6% of this breakdownCanada: 270 citing papers, 3.6% of this breakdownFrance: 254 citing papers, 3.4% of this breakdownAustralia: 223 citing papers, 3% of this breakdownJapan: 182 citing papers, 2.4% of this breakdownSwitzerland: 146 citing papers, 1.9% of this breakdown
0%19.6%Other 26.5%

Fields

  • Medicine87.6%
  • Biochemistry, Genetics and Molecular Biology7.4%
  • Engineering3%
  • Environmental Science0.5%
  • Computer Science0.3%
  • Immunology and Microbiology0.2%
  • Other1%

Topics

  • Cardiomyopathy and Myosin Studies19.9%
  • Cardiovascular Function and Risk Factors11%
  • Cardiovascular Effects of Exercise8.1%
  • Cardiac electrophysiology and arrhythmias4.4%
  • Cardiac Imaging and Diagnostics4.3%
  • Cardiac pacing and defibrillation studies3.2%
  • Other49.1%

Coauthors

All papers

Open in search
  1. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2014 cited by 4,317

  2. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , - Circulation 2018 cited by 831

  3. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases

    Authors: , , , , , , , , , , , , , , , - European Heart Journal 2007 cited by 2,998

  4. Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2014 cited by 1,036

  5. Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction

    Authors: , , , , , , , , , - Circulation 2006 cited by 1,109

  6. Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy

    Authors: , , , , , , , - New England Journal of Medicine 2003 cited by 1,468

  7. Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy

    Authors: , , , , , - Circulation 2001 cited by 859

  8. An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease

    Authors: , , , , , , , , , , , , - European Journal of Heart Failure 2020 cited by 219

  9. Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , - Journal of the American College of Cardiology 2005 cited by 809

  10. Patterns of Disease Progression in Hypertrophic Cardiomyopathy

    Authors: , , , - Circulation Heart Failure 2012 cited by 347

  11. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frank Weidemann, Frits A. Wijburg, Peter Woolfson, Carla E. M. Hollak - Orphanet Journal of Rare Diseases 2015 cited by 345

  12. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Issa Farah Issa, James Malcolmson, Tom Burns, Neha Sekhri, Christopher W. Hoeger, Rumana Omar, Perry Elliott - Circulation 2017 cited by 209

  13. Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , - Circulation Heart Failure 2016 cited by 157

  14. Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , - Journal of the American College of Cardiology 2005 cited by 434

  15. Obesity and its Association to Phenotype and Clinical Course in Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2013 cited by 177

  16. Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations

    Authors: , , , , , , , , , , , , , - Journal of the American College of Cardiology 2014 cited by 170

  17. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy

    Authors: , , , , , , , , , - Journal of the American College of Cardiology 2002 cited by 399

  18. Pharmacological Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives

    Authors: , , , , , - European Journal of Heart Failure 2016 cited by 146

  19. Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy

    Authors: , , , , , - New England Journal of Medicine 2003 cited by 771

  20. Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , - Circulation Heart Failure 2015 cited by 101

  21. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy

    Authors: , , , , , , , , , , , , , , , - International Journal of Cardiology 2019 cited by 100

  22. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study

    Authors: , , , , , , , , , , , , , , , - Molecular Genetics & Genomic Medicine 2018 cited by 110

  23. Italian Cardiological Guidelines (COCIS) for Competitive Sport Eligibility in athletes with heart disease: update 2020

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Cardiovascular Medicine 2021 cited by 63

  24. Epidemiology of Hypertrophic Cardiomyopathy–Related Death

    Authors: , , , , , , , , - Circulation 2000 cited by 795